SCHEMBL15415745

SCHEMBL15415745

O=C1CCN(c2ncc(Br)c(C(F)(F)F)n2)CCN1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRB1 P08588 1/20 0.39
OPRM1 P35372 1/20 0.39
OPRL1 P41146 1/20 0.39
NR1H3 Q13133 1/20 0.36
NR1H2 P55055 1/20 0.36
PIK3CA P42336 2/20 0.36
EIF2AK4 Q9P2K8 1/20 0.35
ALDH1A1 P00352 3/20 0.34
CYP2C19 P33261 2/20 0.34
TSHR P16473 2/20 0.34
CYP1A2 P05177 1/20 0.34
CYP3A4 P08684 1/20 0.34
HPGD P15428 1/20 0.34
CASP1 P29466 1/20 0.34
CASP7 P55210 1/20 0.34
HSD17B10 Q99714 1/20 0.34
ATF1 P18846 1/20 0.34
NFKB1 P19838 1/20 0.34
ABL1 P00519 1/20 0.34
BCR P11274 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21768428 0.89 OPRM1 (0.48) ADRB1OPRM1OPRL1NR1H3NR1H2
SCHEMBL31074176 0.79 LCAT (0.42) ADRB1PIK3CAALDH1A1
SCHEMBL21768445 0.75 OPRL1 (0.43) OPRL1NR1H3NR1H2ALDH1A1CYP2C19
SCHEMBL21768443 0.74 ALDH1A1 (0.58) PIK3CAALDH1A1TSHRABL1BCR
SCHEMBL19145317 0.73 OPRM1 (0.50) ADRB1OPRM1OPRL1PIK3CAALDH1A1
SCHEMBL21768436 0.72 OPRL1 (0.46) OPRL1NR1H3NR1H2EIF2AK4ALDH1A1
SCHEMBL19105592 0.72 OPRM1 (0.49) ADRB1OPRM1OPRL1NR1H3NR1H2
SCHEMBL21780676 0.72 OPRM1 (0.49) ADRB1OPRM1OPRL1NR1H3NR1H2
SCHEMBL15509230 0.69 OPRM1 (0.46) OPRM1OPRL1PIK3CAALDH1A1CYP2C19
SCHEMBL15416439 0.68 PIK3CA (0.37) OPRM1OPRL1PIK3CAEIF2AK4ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2872508-B1 IMIDAZOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY UCB BIOPHARMA SPRL (BE) 2018-08-29 EP disclosed
US-9309243-B2 Imidazopyridine derivatives as modulators of TNF activity UCB BIOPHARMA SPRL (BE) 2016-04-12 US disclosed
US-20150203486-A1 Imidazopyridine Derivatives as Modulators of TNF Activity UCB Biopharma SPRL a corporation 2015-07-23 US disclosed
EP-2872508-A1 IMIDAZOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY UCB Biopharma SPRL (BE) 2015-05-20 EP disclosed
WO-2014009295-A1 IMIDAZOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY UCB PHARMA S.A. (BE) 2014-01-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150203486-A1 Imidazopyridine Derivatives as Modulators of TNF Activity TNF, TNFRSF1A, IL1A ADRB1 318/4885OPRM1 572/4885OPRL1 122/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.